ARCHIVES

PDX Shows 27% Response In T-Cell Lymphoma In Study

This article is from The Cancer Letter archive.

Vol. 31 No. 12 | December 26, 2008

Download PDF Visit The Full Archive

Related Articles

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

May 22, 1981

Take Program Direction Away From CCIRC, Form New Group for Clinical Trials, Conferees Suggest

June 6, 1975

New Group Review First NTP Reports, Gets Job On Permanent Basis, Wrangles Over Extrapolation

July 11, 1980

Herceptin Lowers Recurrence In Early Breast Cancer

November 25, 2005

Funding Opportunities: Komen Foundation Seeks Reviewers

February 28, 1997

Research Policy: NIH Trials Don’t Enroll Enough Women to Allow Analysis, GAO Says in Report

May 12, 2000